HDFC MF and ADIA Lead Major ₹777 Crore Block Deal in Corona Remedies
A massive liquidity event unfolded in the pharmaceutical sector as Sepia Investments and Anchor Partners offloaded significant stakes in Corona Remedies Limited. This high-value block deal attracted a heavy-weight lineup of domestic and international institutional investors, signaling strong confidence in the company's long-term prospects.
Breakdown of the Mega Divestment
On June 17, 2026, the stock exchange witnessed a substantial transfer of ownership in Corona Remedies. The primary seller, Sepia Investments, divested 43,28,943 shares at a price of ₹1,730 per share, amounting to approximately ₹748.9 crore.
Adding to this exit, Anchor Partners also offloaded 1,61,861 shares at the same price point of ₹1,730, contributing an additional ₹28 crore to the transaction. In total, these two sellers collectively exited positions worth roughly ₹776.9 crore in the pharmaceutical major.
HDFC Mutual Fund Dominates the Buy Side
The transaction saw participation from twelve distinct institutional buyers, with HDFC Mutual Fund emerging as the most aggressive acquirer. By purchasing 24,50,000 shares, HDFC MF invested approximately ₹423.9 crore, effectively absorbing more than half of the total deal value.
The buy-side appetite was further bolstered by several other major players:
- Aditya Birla Sun Life Mutual Fund: Acquired 4,90,000 shares worth ₹84.8 crore.
- Aberdeen Asian Smaller Companies Investment Trust Plc: Bought 4,50,868 shares for roughly ₹78 crore.
- Invesco Mutual Fund: Picked up 2,89,017 shares valued at ₹50 crore.
- Aberdeen Standard Sicav I: Acquired 2,74,132 shares worth ₹47.4 crore.
Global Institutional Interest in Corona Remedies
Beyond domestic mutual funds, the deal highlighted significant interest from global sovereign wealth and international asset management firms. The Abu Dhabi Investment Authority (ADIA) participated in the deal, acquiring 39,130 shares worth approximately ₹6.8 crore.
Outros participantes internacionais notáveis incluíram o WhiteOak Capital Mutual Fund, que investiu ₹25,1 crore, e o India Acorn ICAV - Ashoka WhiteOak Emerging Markets Equity Fund, que gastou ₹25,7 crore. O negócio também contou com participações menores do Kotak Mahindra Mutual Fund (₹28 crore), Factory Mutual Insurance Company (₹1,9 crore) e TCW White Oak Emerging Markets Equity Fund (₹33 lakh), demonstrando um consenso institucional abrangente sobre a avaliação da ação.
Principais Conclusões
- Evento de Liquidez Massivo: O desinvestimento total da Sepia Investments e da Anchor Partners atingiu aproximadamente ₹776,9 crore a um preço de ₹1.730 por ação.
- Posição Dominante do HDFC MF: O HDFC Mutual Fund foi o comprador principal, representando mais de 50% do valor do negócio com um investimento de ₹423,9 crore.
- Base de Investidores Diversificada: O negócio apresentou uma mistura saudável de fundos mútuos domésticos indianos e gigantes globais como ADIA e Aberdeen, indicando uma forte confiança institucional na Corona Remedies.